Quality of Life in Lymphoma Patients One Year Post-chemotherapy
QUALIPSO-L
1 other identifier
observational
600
1 country
1
Brief Summary
Malignant lymphomas are considered as among the most chemo-sensitive cancers. ML are cured in more than 85% of patient, the majority with complete response. After this active phase of treatment, patients are in "after cancer period". Toulouse University Hospital developed since 2006 the Ambulatory Medical Assistance for After Cancer program on lymphoma patient. Ambulatory Medical Assistance for After Cancer is very efficient for detecting physical and psychological complications which impact quality of life. The investigators identified 22% of lymphoma patients who had a reduced quality of life one year after the end of chemotherapy. The present study aims to investigate the evolution of observed complications and identify cancer care pathway which decrease the quality of life reduction risk in patients one year after lymphoma chemotherapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 27, 2019
CompletedFirst Posted
Study publicly available on registry
December 5, 2019
CompletedStudy Start
First participant enrolled
January 28, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedSeptember 21, 2023
September 1, 2023
5.3 years
November 27, 2019
September 18, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Quality of life change: Quality of Life-C30 French version
Health-related quality of life is evaluated by the use of Quality of Life-C30 French version
Change from baseline quality of life at 12 month
Study Arms (1)
Lymphoma patients
Patients being in complete response after a first therapy for malignant lymphoma.
Interventions
Eligibility Criteria
Patients with lymphoma
You may qualify if:
- Patients being in complete response after a first therapy for lymphoma
- Malignant lymphoma (Hodgkin or non-Hodgkin) treated by anthracyclines with a minimum of 6 cycles, followed or not by autologous hematopoietic stem cell transplantation
- Patients informed of the study and not opposed to the research
You may not qualify if:
- Patients under legal guardian .
- Patients unavailable to formulate non-opposition to the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital, Toulouselead
- Force Hématocollaborator
- Hospitalideecollaborator
Study Sites (1)
University Hospital Toulouse
Toulouse, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Loïc YSEBAERT, MD, PhD
University Hospital, Toulouse
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 27, 2019
First Posted
December 5, 2019
Study Start
January 28, 2020
Primary Completion
June 1, 2025
Study Completion
June 1, 2025
Last Updated
September 21, 2023
Record last verified: 2023-09
Data Sharing
- IPD Sharing
- Will not share